BSPM: AI 评分 47/100 — AI 分析 (4月 2026)

Biostar Pharmaceuticals, Inc. focuses on developing, manufacturing, and marketing pharmaceutical products in China. Its portfolio includes both over-the-counter (OTC) and prescription medications, targeting a range of conditions with a focus on traditional Chinese medicine.

Key Facts: AI Score: 47/100 Sector: Healthcare

公司概况

概要：

Biostar Pharmaceuticals, Inc., based in China, develops and markets OTC and prescription pharmaceutical products, including its key product Xin Ao Xing Oleanolic Acid capsule for chronic hepatitis B. The company distributes its products across 28 provinces in China, leveraging both distributors and a direct sales network.

BSPM是做什么的？

Biostar Pharmaceuticals, Inc., established in 2007 and headquartered in Xianyang, China, is engaged in the development, manufacture, and marketing of pharmaceutical products. The company's portfolio includes both over-the-counter (OTC) and prescription medications, addressing a variety of diseases and conditions prevalent in the Chinese market. Its primary product is Xin Ao Xing Oleanolic Acid capsule, an OTC medicine indicated for chronic hepatitis B, a significant health concern in China. In addition to Xin Ao Xing, Biostar offers 12 other OTC products and 17 prescription-based pharmaceuticals, catering to a broad spectrum of healthcare needs. Biostar's OTC product line includes Ganwang compound paracetamol and amantadine hydrochloride capsule for cold and flu symptoms, Tianqi Dysmenorrhea capsule for menstrual pain, Deafness Tongqiao pills for ear-related issues, Wenweishu capsules for chronic gastritis, Zhitongtougu ointment for joint pain, and Chuzhang Zehaifu tablets for cataract. The company's prescription drugs cover areas such as cardiovascular health (Danshen granules and tablets), pediatric care (Taohuasan), and various other conditions including rhinitis, hyperthyroidism, and bacterial infections. Biostar also operates an online platform, the China Hepatitis Internet hospital, providing information and treatment options for HBV patients, as well as facilitating the purchase of HBV medicines. The company distributes its products through a network of distributors and sales personnel, reaching approximately 28 provinces across China.

BSPM的投资论点是什么？

Biostar Pharmaceuticals operates in the Chinese pharmaceutical market, focusing on both OTC and prescription drugs. The company's key product, Xin Ao Xing Oleanolic Acid capsule for chronic hepatitis B, addresses a significant health issue in China. However, with a negative profit margin of -239.0% and a market capitalization of $0.00B, the company faces significant financial challenges. Potential growth catalysts include expanding its product line and increasing its market penetration within China. Investors should carefully consider the risks associated with investing in OTC-listed companies, including liquidity and disclosure concerns.

BSPM在哪个行业运营？

Biostar Pharmaceuticals operates within the Chinese pharmaceutical market, a large and rapidly growing sector driven by increasing healthcare expenditure and an aging population. The market is characterized by a mix of domestic and international players, with a growing demand for both OTC and prescription drugs. Biostar competes with other generic drug manufacturers, including BIOCQ, CLVR, CRFTF, CWWBF, and ELOX, as well as larger multinational pharmaceutical companies. The company's focus on traditional Chinese medicine and its established distribution network provide a competitive advantage in certain segments of the market.

Drug Manufacturers - Specialty & Generic

Healthcare

BSPM有哪些增长机遇？

Expanding its OTC product line: Biostar can capitalize on the growing demand for OTC medications in China by introducing new products targeting common ailments. The Chinese OTC market is projected to reach $50 billion by 2028, offering significant revenue potential. Timeline: Launching 2-3 new OTC products annually over the next 3-5 years could significantly boost revenue.
Increasing market penetration in existing provinces: Biostar currently operates in 28 provinces in China. Deepening its market penetration within these regions through targeted marketing and sales initiatives can drive revenue growth. The pharmaceutical market in these provinces is estimated at $200 billion, offering ample opportunity for expansion. Timeline: Achieving a 1% increase in market share in each province over the next 2 years.
Leveraging its online platform: Biostar's China Hepatitis Internet hospital provides a direct channel to reach HBV patients. Expanding the platform's services and offerings, such as online consultations and prescription refills, can enhance customer engagement and drive sales. The online healthcare market in China is projected to reach $40 billion by 2027. Timeline: Expanding online services and increasing user engagement by 20% annually.
Developing new prescription drugs: Biostar can invest in research and development to create new prescription drugs targeting unmet medical needs in China. The prescription drug market in China is projected to reach $300 billion by 2028. Timeline: Launching 1-2 new prescription drugs every 3 years.
Strategic partnerships and acquisitions: Biostar can explore strategic partnerships or acquisitions to expand its product portfolio, market reach, and technological capabilities. The Chinese pharmaceutical market is consolidating, presenting opportunities for strategic alliances. Timeline: Pursuing 1-2 strategic partnerships or acquisitions over the next 5 years.

Gross Margin of 38.4% indicates potential for profitability if costs are managed effectively.
Operates in 28 provinces in China, demonstrating a significant distribution network.
Offers both OTC and prescription drugs, diversifying its revenue streams.
Key product, Xin Ao Xing Oleanolic Acid capsule, targets chronic hepatitis B, a significant health issue in China.
Profit Margin of -239.0% signals financial challenges requiring strategic intervention.

BSPM提供哪些产品和服务？

Develops over-the-counter (OTC) pharmaceutical products.
Manufactures prescription pharmaceutical products.
Markets pharmaceutical products for various diseases and conditions.
Offers Xin Ao Xing Oleanolic Acid capsule for chronic hepatitis B.
Provides traditional Chinese medicines.
Operates an online platform for HBV patients.

BSPM如何赚钱？

Develops and manufactures OTC and prescription pharmaceutical products.
Sells products through distributors and a network of sales people in China.
Operates an online platform (China Hepatitis Internet hospital) for HBV patients.
Generates revenue from the sale of pharmaceutical products.

Patients in China seeking OTC medications for common ailments.
Patients in China requiring prescription medications for various diseases.
Hospitals and clinics in China that purchase pharmaceutical products.
Distributors who sell Biostar's products to pharmacies and other retailers.

Established distribution network in 28 provinces in China.
Focus on traditional Chinese medicine.
Key product targeting chronic hepatitis B, a significant health issue in China.
Online platform providing direct access to HBV patients.

什么因素可能推动BSPM股价上涨？

Upcoming: Potential regulatory approvals for new pharmaceutical products.
Ongoing: Expansion of the company's distribution network in China.
Ongoing: Increased adoption of the China Hepatitis Internet hospital platform.

BSPM的主要风险是什么？

Potential: Competition from larger pharmaceutical companies.
Potential: Regulatory changes in China.
Ongoing: Fluctuations in raw material prices.
Ongoing: Economic slowdown in China.
Ongoing: Negative profit margin and limited financial resources.

BSPM的核心优势是什么？

Established distribution network in China.
Portfolio of both OTC and prescription drugs.
Focus on traditional Chinese medicine.
Online platform for HBV patients.

BSPM的劣势是什么？

Negative profit margin.
Limited financial resources.
Dependence on a single key product (Xin Ao Xing).
OTC listing indicates higher risk.

BSPM有哪些机遇？

Expanding OTC product line.
Increasing market penetration in existing provinces.
Leveraging online platform for growth.
Developing new prescription drugs.

BSPM面临哪些威胁？

Competition from larger pharmaceutical companies.
Regulatory changes in China.
Fluctuations in raw material prices.
Economic slowdown in China.

BSPM的竞争对手是谁？

BioCryst Pharmaceuticals, Inc. — Focuses on novel small-molecule drugs. — (BIOCQ)
Clever Leaves Holdings Inc. — Cultivates and extracts medicinal cannabis. — (CLVR)
Cara Therapeutics, Inc. — Develops therapies for pain and pruritus. — (CRFTF)
CWW Minerals Holdings Corp. — Unknown business focus. — (CWWBF)
Eloxx Pharmaceuticals, Inc. — Develops RNA-modulating therapeutics. — (ELOX)

Key Metrics

MoonshotScore: 47/100

Company Profile

CEO: Ronghua Wang
Headquarters: Xianyang, CN
Employees: 200
Founded: 2008

AI Insight

AI analysis pending for BSPM

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Biostar Pharmaceuticals, Inc. do?

Biostar Pharmaceuticals, Inc. is a Chinese pharmaceutical company that develops, manufactures, and markets both over-the-counter (OTC) and prescription drugs. Its primary focus is on addressing common diseases and conditions in China, with a key product being Xin Ao Xing Oleanolic Acid capsule for chronic hepatitis B. The company distributes its products through a network of distributors and sales personnel, as well as through its online platform, the China Hepatitis Internet hospital, reaching patients across 28 provinces in China.

What do analysts say about BSPM stock?

AI analysis is currently pending for Biostar Pharmaceuticals, Inc. (BSPM). Given its OTC listing and negative profit margin, investors should conduct thorough due diligence and carefully assess the risks associated with investing in this company. Key valuation metrics, such as price-to-earnings ratio, are currently not meaningful due to the company's lack of profitability. Growth considerations include the potential for expanding its product line and increasing its market penetration within China.

What are the main risks for BSPM?

The main risks for Biostar Pharmaceuticals, Inc. include its negative profit margin, limited financial resources, and dependence on a single key product. As an OTC-listed company, BSPM faces additional risks related to liquidity, disclosure, and regulatory oversight. Competition from larger pharmaceutical companies and regulatory changes in China also pose significant challenges. Investors should carefully consider these risks before investing in BSPM.